One study [58] found that NLRP3 inflammatory vesicles may play a role in high glucose-induced glomerular thylakoid cell activation and inflammation, and that naringin alleviates glomerular thylakoid cell injury by inhibiting NLRP3/caspase-1/ IL-1β signaling pathway-mediated expression of inflammatory factors as a potential new therapy for DN. The gene discussed is CASP1; the disease is liver dysplastic nodule.